Search

Your search keyword '"Moacyr Jesus Barreto de Melo Rêgo"' showing total 4 results
Start Over Author "Moacyr Jesus Barreto de Melo Rêgo" Journal autoimmunity
4 results on '"Moacyr Jesus Barreto de Melo Rêgo"'

1. Genetic variants in LGALS3 are related to lower galectin-3 serum levels and clinical outcomes in systemic sclerosis patients: A case-control study

Author

Eudes Gustavo Constantino Cunha, Camilla Albertina Dantas de Lima, Kamila de Melo Vilar, Marcelo Francisco de Nóbrega, Anderson Rodrigues de Almeida, Michelly Cristiny Pereira, Andréa Tavares Dantas, Rafaela Silva Guimarães Gonçalves, Moacyr Jesus Barreto de Melo Rêgo, Angela Luzia Branco Pinto Duarte, and Maira Galdino da Rocha Pitta

Subjects
scleroderma, lgals3, galectin-3, glycobiology, polymorphism, Internal medicine, RC31-1245
Abstract

Introduction Systemic sclerosis (SSc) is a rare complex disease characterized by vascular damage, autoimmunity, and extensive skin and internal organs fibrosis. Galectin-3 (Gal-3) is encoded by gene LGALS3 (Lectin, Galactoside-Binding, Soluble, 3; 14q22.3) and it has been reported to play a central role in self-tolerance, inflammation, and fibrosis. Objective To investigate associations among LGALS3 single nucleotide polymorphisms (SNPs) and serum levels Gal-3 and SSc susceptibility and their clinical features. Methods A case-control study with 88 patients and 151 matched controls was performed. LGALS3 variants were analyzed by the TaqMan real-time polymerase chain reaction (PCR) system whereas Gal-3 serum levels were measured by sandwich enzyme linked immunosorbent assay (ELISA). Associations among genotypes, clinical features, and Gal-3 levels were performed by univariable and multivariable analysis through statistical packages. Results The LGALS3 rs4652 A/C genotype was more frequent in SSc patients than controls according to overdominant model [OR 1.89 (CI 95% 1.01 − 3.52); p = .046]. Also, LGALS3 rs4652 C/C polymorphic genotype was associated with lower patient Gal-3 levels (p = .03) and control group (p = 0.005), as noted by generalized linear model (GLM). The LGALS3 rs1009977 G/T controls showed higher Gal-3 levels than wild-type and polymorphic genotypes (p = .03); however, in SSc patients, no difference was found. None of the LGALS3 SNPs or Gal-3 levels was associated with clinical manifestations in SSc patients. Considering only the SSc group, GLM analysis pointed LGALS3 rs4652 and rs2075601, pulmonary arterial hypertension (PAH), myopathy, and health assessment questionnaire (HAQ) and scleroderma health assessment questionnaire (SHAQ) as important predictors for Gal-3 levels. Conclusion The LGALS3 rs4652 A/C was more frequent in SSc patients and related to lower Gal-3 levels. These findings were corroborated through a GLM to estimate Gal-3 values. Also, by model equations, Gal-3 levels may be predicted by HAQ, SHAQ, PAH, myopathy, and LGALS3 rs4652 and rs2075601 factors. In these ways, we suggest that galectins may be promising biomarkers to identify susceptibility to SSc as well as to identify HAQ, SHAQ, PAH, and myopathy outcomes.

Published
2021
Full Text
View/download PDF

2. Genetic variants in

Author

Eudes Gustavo Constantino, Cunha, Camilla Albertina Dantas, de Lima, Kamila de Melo, Vilar, Marcelo Francisco de, Nóbrega, Anderson Rodrigues de, Almeida, Michelly Cristiny, Pereira, Andréa Tavares, Dantas, Rafaela Silva Guimarães, Gonçalves, Moacyr Jesus Barreto de Melo, Rêgo, Angela Luzia Branco Pinto, Duarte, and Maira Galdino da Rocha, Pitta

Subjects
Scleroderma, Systemic, Case-Control Studies, Galectin 3, Galectins, Humans, Blood Proteins, Polymorphism, Single Nucleotide
Abstract

Systemic sclerosis (SSc) is a rare complex disease characterized by vascular damage, autoimmunity, and extensive skin and internal organs fibrosis. Galectin-3 (Gal-3) is encoded by geneTo investigate associations amongA case-control study with 88 patients and 151 matched controls was performed.TheThe

Published
2021

3. IL-17 and related cytokines involved in systemic sclerosis: Perspectives

Author

Maira Galdino da Rocha Pitta, Angela Luzia Branco Pinto Duarte, Anderson Rodrigues de Almeida, Michelly Cristiny Pereira, Andréa Tavares Dantas, Ivan da Rocha Pitta, Rafaela Silva Guimarães Gonçalves, Moacyr Jesus Barreto de Melo Rêgo, and Claudia Diniz Lopes Marques

Subjects
030203 arthritis & rheumatology, 0301 basic medicine, Scleroderma, Systemic, Vascular disease, business.industry, Interleukin-17, Immunology, Inflammation, Disease, medicine.disease, Pathophysiology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Immune system, Fibrosis, medicine, Humans, Th17 Cells, Immunology and Allergy, Interleukin 17, medicine.symptom, business, Rare disease
Abstract

Systemic sclerosis (SSc) is a multisystemic, complex, and rare disease of connective tissue, with high morbidity and mortality, and without specific treatment. The disease is characterized by three main principles: vascular disease, autoantibody production and inflammation, and fibrosis. Since it is well defined that SSc is characterized by elevated production of TGF-β, IL-6, and IL-1, all of them cytokines related to Th17 differentiation, the hypothesis is that this disease may be strongly related to a polarization of the immune response towards the Th17 pathway. Considering the importance of a better understanding of the pathophysiology of Th17 pathway in SSc, this article aims to propose an update for a better understanding of current knowledge on main cytokines secreted by the Th17 cells (IL-17 A, IL-21, and IL-22) and the future prospects in the current disease.

Published
2017
Full Text
View/download PDF

4. Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29)

Author

Maira Galdino da Rocha Pitta, Angela Luzia Branco Pinto Duarte, Anderson Rodrigues de Almeida, Moacyr Jesus Barreto de Melo Rêgo, Michelly Cristiny Pereira, Andréa Tavares Dantas, Claudia Diniz Lopes Marques, Sayonara Maria Calado Gonçalves, and Ivan da Rocha Pitta

Subjects
Adult, Male, medicine.medical_treatment, Immunology, Gene Expression, Scleroderma, Correlation, Pathogenesis, Interferon-gamma, Interferon, medicine, Immunology and Allergy, Humans, Interferon gamma, Interleukin 29, Muscle, Skeletal, Aged, Antitumor activity, Scleroderma, Systemic, Myositis, business.industry, Interleukins, Middle Aged, medicine.disease, Cytokine, Case-Control Studies, Female, Interferons, business, medicine.drug
Abstract

Interferon (IFN)-λ1 is a newly described cytokine, member of type III interferons family, which is known for its antiviral, anti-proliferative and antitumor activity. Recent studies indicated that this cytokine has also immune-regulatory function, but its role in the pathogenesis of autoimmune diseases is not established yet. We evaluated serum levels of IFN-λ1 in systemic sclerosis (SSc) patients and healthy controls and its association with IFN-γ and clinical manifestations.IFN-λ1 and IFN-γ serum levels were measured by ELISA from 52 patients with SSc and 53 healthy controls. Association of cytokines serum levels was sought with clinical parameters.IFN-λ1 and IFN-γ levels in SSc patients were significantly higher than those in healthy individuals (24.82 ± 8.78 and 11.04 ± 3.04 pg/ml, p 0.0001; 34.11 ± 8.11 and 10.73 ± 2.77 pg/ml, p 0.0001, respectively). We found a positive correlation between IFN-λ1 and IFN-γ levels in SSc patients (p = 0.0103, r = 0.3526). IFN-γ levels were associated with muscle involvement (p = 0.0483).We first showed raised IFN-λ1 levels in SSc patients. Furthermore, we found a correlation between IFN-λ1 and IFN-γ levels and an association between IFN-γ and myositis. Additional in vitro and in vivo studies are needed to understand IFN-λ1 role in SSc.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results